Woulgan patent approved

Biotec Pharmacon ASA has received a Notice of Allowance for its Woulgan gel in the US.

The allowed patent application has the application number US 13/989,594, title of invention: Glucan Gels. The claims cover the gel glucan product comprising SBG, a method of producing the gel glucan product and the product obtainable by this method as well as a medical composition comprising the gel glucan.

“We are very pleased with this patent as it will open up for opportunities in the important US market. The US market represents approximately one third of global wound market”, says Svein Lien, CEO, Biotec Pharmacon ASA

About Biotec Pharmacon ASA: Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel immunomodulating products, including Woulgan®, a premium priced product in the advanced wound care market. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics, representing growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.